China NMPA approves Keymed Biosciences’ sNDA for Stapokibart to treat chronic rhinosinusitis with nasal polyposis: Chengdu, China Thursday, December 26, 2024, 18:00 Hrs [IST] Ke ...
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of patients with ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
RAPT (RAPT) stock rallied as much as 180% Monday after the company announced a licensing deal with China's Jemincare and a $150M private placement of its stock. Read more here.
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement ...
RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on ...
The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III clinical study to confirm the efficacy and safety of Stapokibart injection in treatment of ...
Changes are coming to the cold and cough aisle of your local pharmacy: U.S. officials are moving to phase out the leading ...
A Chicago man was stuck with a big medical bill after undergoing a colonoscopy that found no evidence of cancer. Here's why.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback